Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation

Science Translational Medicine

Volumn 4, Issue 144, 2012, Pages

  Choi, Jason C ^a   Muchir, Antoine ^a   Wu, Wei ^a   Iwata, Shinichi ^a   Homma, Shunichi ^a   Morrow, John P ^a   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PROTEIN KINASE B; SELUMETINIB; TEMSIROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOPHAGY; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LAMIN A GENE; LAMIN C GENE; MOUSE; MUTATOR GENE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CARDIOMYOPATHIES; LAMIN TYPE A; MUTATION; RATS; SIROLIMUS;

EID: 84864524683     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003875     Document Type: Review

References (48)

1. W. T. Dauer, H. J. Worman, The nuclear envelope as a signaling node in development and disease. Dev. Cell 17, 626-638 (2009).
2. J. T. Lu, A. Muchir, P. L. Nagy, H. J. Worman, LMNA cardiomyopathy: Cell biology and genetics meet clinical medicine. Dis. Model. Mech. 4, 562-568 (2011).
3. L. Hernandez, K. J. Roux, E. S. Wong, L. C. Mounkes, R. Mutalif, R. Navasankari, B. Rai, S. Cool, J. W. Jeong, H. Wang, H. S. Lee, S. Kozlov, M. Grunert, T. Keeble, C. M. Jones, M. D. Meta, S. G. Young, I. O. Daar, B. Burke, A. O. Perantoni, C. L. Stewart, Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev. Cell 19, 413-425 (2010).
4. K. Cao, J. J. Graziotto, C. D. Blair, J. R. Mazzulli, M. R. Erdos, D. Krainc, F. S. Collins, Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci. Transl. Med. 3, 89ra58 (2011).
5. A. Muchir, P. Pavlidis, V. Decostre, A. J. Herron, T. Arimura, G. Bonne, H. J. Worman, Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J. Clin. Invest. 117, 1282-1293 (2007).
6. A. Muchir, S. A. Reilly, W. Wu, S. Iwata, S. Homma, G. Bonne, H. J. Worman, Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene. Cardiovasc. Res. 93, 311-319 (2012).
7. A. Muchir, J. Shan, G. Bonne, S. E. Lehnart, H. J. Worman, Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum. Mol. Genet. 18, 241-247 (2009).
8. W. Wu, A. Muchir, J. Shan, G. Bonne, H. J. Worman, Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 123, 53-61 (2011).
9. Y. Fujio, T. Nguyen, D. Wencker, R. N. Kitsis, K. Walsh, Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101, 660-667 (2000).
10. T. Matsui, J. Tao, F. del Monte, K. H. Lee, L. Li, M. Picard, T. L. Force, T. F. Franke, R. J. Hajjar, A. Rosenzweig, Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104, 330-335 (2001).
11. J. A. Kuzman, T. D. O'Connell, A. M. Gerdes, Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 148, 3477-3484 (2007).
12. T. M. Marin, K. Keith, B. Davies, D. A. Conner, P. Guha, D. Kalaitzidis, X. Wu, J. Lauriol, B. Wang, M. Bauer, R. Bronson, K. G. Franchini, B. G. Neel, M. I. Kontaridis, Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121, 1026-1043 (2011).
13. H. A. Baba, J. Stypmann, F. Grabellus, P. Kirchhof, A. Sokoll, M. Schäfers, A. Takeda, M. J. Wilhelm, H. H. Scheld, N. Takeda, G. Breithardt, B. Levkau, Dynamic regulation of MEK/Erks and Akt/GSK-3 b in human end-stage heart failure after left ventricular mechanical support: Myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc. Res. 59, 390-399 (2003).
14. S. Haq, G. Choukroun, H. Lim, K. M. Tymitz, F. del Monte, J. Gwathmey, L. Grazette, A. Michael, R. Hajjar, T. Force, J. D. Molkentin, Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103, 670-677 (2001).
15. V. Karoor, S. F. Vatner, G. Takagi, G. Yang, J. Thaisz, J. Sadoshima, D. E. Vatner, Propranolol prevents enhanced stress signaling in Gsα cardiomyopathy: Potential mechanism for β-blockade in heart failure. J. Mol. Cell. Cardiol. 36, 305-312 (2004).
16. T. Arimura, A. Helbling-Leclerc, C. Massart, S. Varnous, F. Niel, E. Lacène, Y. Fromes, M. Toussaint, A. M. Mura, D. I. Keller, H. Amthor, R. Isnard, M. Malissen, K. Schwartz, G. Bonne, Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum. Mol. Genet. 14, 155-169 (2005).
17. H. C. Dan, M. Sun, L. Yang, R. I. Feldman, X. M. Sui, C. C. Ou, M. Nellist, R. S. Yeung, D. J. Halley, S. V. Nicosia, W. J. Pledger, J. Q. Cheng, Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277, 35364-35370 (2002).
18. K. Inoki, Y. Li, T. Zhu, J. Wu, K. L. Guan, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 (2002).
19. B. D. Manning, A. R. Tee, M. N. Logsdon, J. Blenis, L. C. Cantley, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10, 151-162 (2002).
20. C. J. Potter, L. G. Pedraza, T. Xu, Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4, 658-665 (2002).
21. Y. Sancak, C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr, D. M. Sabatini, PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915 (2007).
22. E. Vander Haar, S. I. Lee, S. Bandhakavi, T. J. Griffin, D. H. Kim, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9, 316-323 (2007).
23. R. Zoncu, A. Efeyan, D. M. Sabatini, mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
24. Y. Ding, X. Sun, W. Huang, T. Hoage, M. Redfield, S. Kushwaha, S. Sivasubbu, X. Lin, S. Ekker, X. Xu, Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circ. Res. 109, 658-669 (2011).
25. J. R. McMullen, M. C. Sherwood, O. Tarnavski, L. Zhang, A. L. Dorfman, T. Shioi, S. Izumo, Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109, 3050-3055 (2004).
26. T. Shioi, J. R. McMullen, O. Tarnavski, K. Converso, M. C. Sherwood, W. J. Manning, S. Izumo, Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664-1670 (2003).
27. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, P. P. Pandolfi, Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193 (2005).
28. D. D. Sarbassov, S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, D. M. Sabatini, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006).
29. Z. Zeng, D. D. Sarbassov, I. J. Samudio, K. W. Yee, M. F. Munsell, C. Ellen Jackson, F. J. Giles, D. M. Sabatini, M. Andreeff, M. Konopleva, Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109, 3509-3512 (2007).
30. J. Huang, B. D. Manning, A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222 (2009).
31. G. Kroemer, G. Mariño, B. Levine, Autophagy and the integrated stress response. Mol. Cell 40, 280-293 (2010).
32. B. Levine, G. Kroemer, Autophagy in the pathogenesis of disease. Cell 132, 27-42 (2008).
33. A. Nakai, O. Yamaguchi, T. Takeda, Y. Higuchi, S. Hikoso, M. Taniike, S. Omiya, I. Mizote, Y. Matsumura, M. Asahi, K. Nishida, M. Hori, N. Mizushima, K. Otsu, The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 13, 619-624 (2007).
34. M. Taneike, O. Yamaguchi, A. Nakai, S. Hikoso, T. Takeda, I. Mizote, T. Oka, T. Tamai, J. Oyabu, T. Murakawa, K. Nishida, T. Shimizu, M. Hori, I. Komuro, T. S. Takuji Shirasawa, N. Mizushima, K. Otsu, Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 6, 600-606 (2010).
35. P. Tannous, H. Zhu, J. L. Johnstone, J. M. Shelton, N. S. Rajasekaran, I. J. Benjamin, L. Nguyen, R. D. Gerard, B. Levine, B. A. Rothermel, J. A. Hill, Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 105, 9745-9750 (2008).
36. Z. Yang, D. J. Klionsky, Mammalian autophagy: Core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131 (2010).
37. S. Pankiv, T. H. Clausen, T. Lamark, A. Brech, J. A. Bruun, H. Outzen, A. Øvervatn, G. Bjørkøy, T. Johansen, p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131-24145 (2007).
38. N. Mizushima, T. Yoshimori, B. Levine, Methods in mammalian autophagy research. Cell 140, 313-326 (2010).
39. C. Mammucari, G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, S. J. Burden, R. Di Lisi, C. Sandri, J. Zhao, A. L. Goldberg, S. Schiaffino, M. Sandri, FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458-471 (2007).
40. J. Zhao, J. J. Brault, A. Schild, P. Cao, M. Sandri, S. Schiaffino, S. H. Lecker, A. L. Goldberg, FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 6, 472-483 (2007).
41. J. M. González, A. Navarro-Puche, B. Casar, P. Crespo, V. Andrés, Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope. J. Cell Biol. 183, 653-666 (2008).
42. J. I. Jones, D. R. Clemmons, Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 16, 3-34 (1995).
43. R. T. Birse, J. Choi, K. Reardon, J. Rodriguez, S. Graham, S. Diop, K. Ocorr, R. Bodmer, S. Oldham, High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila. Cell Metab. 12, 533-544 (2010).
44. D. Zhang, R. Contu, M. V. Latronico, J. Zhang, R. Rizzi, D. Catalucci, S. Miyamoto, K. Huang, M. Ceci, Y. Gu, N. D. Dalton, K. L. Peterson, K. L. Guan, J. H. Brown, J. Chen, N. Sonenberg, G. Condorelli, MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 120, 2805-2816 (2010).
45. P. Shende, I. Plaisance, C. Morandi, C. Pellieux, C. Berthonneche, F. Zorzato, J. Krishnan, R. Lerch, M. N. Hall, M. A. Rüegg, T. Pedrazzini, M. Brink, Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 123, 1073-1082 (2011).
46. F. J. Ramos, S. C. Chen, M. G. Garelick, D. F. Dai, C. Y. Liao, K. H. Schreiber, V. L. MacKay, E. H. An, R. Strong, W. C. Ladiges, P. S. Rabinovitch, M. Kaeberlein, B. K. Kennedy, Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci. Transl. Med. 4, 144ra103 (2012).
47. T. D. O'Connell, M. C. Rodrigo, P. C. Simpson, Isolation and culture of adult mouse cardiac myocytes. Methods Mol. Biol. 357, 271-296 (2007).
48. M. D. Abramoff, P. J. Magalhaes, S. J. Ram, Image processing with ImageJ. Biophotonics Int. 11, 36-42 (2004).